Karyopharm Therapeutics
Mike joined Karyopharm in December 2020 as Senior Vice President, General Counsel. In his role, Mike leads the legal and compliance functions at Karyopharm, including corporate governance, intellectual property, SEC reporting, global compliance, privacy, and general legal support of all other business activities. Prior to joining Karyopharm, Mike served as Counsel, Business Development for Biogen Inc., where he supported Biogen’s global business development platform. Mike started his legal career at Kirkland & Ellis LLP in Chicago. Mike received a Bachelor of Arts in Political Science and Sociology from Saint Michael’s College and a Juris Doctor from Washington University School of Law.
This person is not in any offices
Karyopharm Therapeutics
13 followers
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).